# OnCo record sysucc-001 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/sysucc-001/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "sysucc-001", "NCT01112826" ;
  schema:name "SYSUCC-001"@en ;
  schema:description "SYSUCC-001 gave a year of low-dose daily capecitabine after standard chemotherapy for early triple-negative breast cancer in China. Fewer women relapsed at five years (83 versus 73 percent) and at ten years (78 versus 67 percent), but the improvement in survival itself did not reach statistical significance."@en ;
  schema:url <https://onco.cc/trials/sysucc-001/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01112826>, <https://doi.org/10.1001/jama.2020.23370>, <https://doi.org/10.1016/S1470-2045(25)00545-5> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/efs/>, <https://onco.cc/terms/hand-foot-syndrome/> ;
  onco:trials <https://onco.cc/trials/create-x/>, <https://onco.cc/trials/geicam-ciboma/> .